DLBCL Discussions: ASH 2021 – ENG


POLARIX
ASH 2021
Part I: Pola-R-CHP - possible new standard in 1st line?


ZUMA-7, TRANSFORM, Belinda
ASH 2021
Part II: CAR-T cells - all over the field data for…
DLBCL – ENG


ZUMA-7, BELINDA, TRANSFORM
ASH 2021
axi-cel, tisa-cel, liso-cel: New CAR-T options for R/R…


ASH 2021
Prevention of CNS relapse after R-CHOP


ZUMA‑7
ASH 2021
Axi-cel - new standard for r/r LBCL patients?


ASH 2021
HD-MTX does not lower SCNS rates in high-risk patients


BELINDA
ASH 2021
Tisa-cel - new CAR-T option for R/R aNHL


POLARIX
ASH 2021
pola-R-CHP vs. R-CHOP: a new standard?
DLBCL – GER/ITA


ZUMA‑7
ASH 2021
Axi Cel: un nuovo standard nel DLBCL recidivato o…


POLARIX
ASH 2021
pola-R-CHP vs. R-CHOP: Neuer Standard?


ASH 2021
La prevenzione della recidiva a carico del sistema…


ZUMA-7, BELINDA, TRANSFORM
ASH 2021
Axi-Cel I Tisa-Cel I Liso-Cel: Drei neue CAR-T-Optionen…
Mantle Cell Lymphoma Discussions: ASH 2021 – ENG


BRUIN
ASH 2021
Part II: The white elephant in the room - BTKi


MCL R2 Elderly
ASH 2021
Part I: Potential change in first-line treatment?
Mantle Cell Lymphoma – ENG


BRUIN
ASH 2021
Next generation BTKI Pirtobrutinib


ASH 2021
Encouraging real world safety and efficacy data of…


MCL Younger
ASH 2021
HiDAC-containing induction before ASCT substantially…


MCL R2 Elderly
ASH 2021
Maintenance with Rituximab-Lenalidomid (R2)


MCL R2 Elderly
ASH 2021
Low-dose lenalidomide added to rituximab maintenance in…


BRUIN
ASH 2021
Pirtobrutinib - promising agent moving forward


MCL R2 Elderly
ASH 2021
Focus on maintenance is critical in MCL


ASH 2021
Glofitamab SUD as monotherapy after Gpt induced high…


BRUIN, BRUIN MCL-321
ASH 2021
Pirtobrutinib shows promising efficacy and safety in…
Mantle Cell Lymphoma – GER/ITA/ESP


ASH 2021
Eficacia y seguridad de brexu-cel en pacientes con LCM…


MCL R2 Elderly
ASH 2021
Añadir lenalidomida a dosis bajas a rituximab en el…


BRUIN, BRUIN MCL-321
ASH 2021
Pirtobrutinib es eficaz y seguro en pacientes muy…


BRUIN
ASH 2021
Pirtobrutinib: Neuer, nicht-kovalenter BTKi


MCL Younger
ASH 2021
La inducción con citarabina a dosis altas antes del…


MCL R2 Elderly
ASH 2021
Ruolo del mantenimento con R2 nel linfoma mantellare


MCL R2 Elderly
ASH 2021
Rituximab-Lenalidomid Erhaltungstherapie (R2)
Follicular Lymphoma Discussions: ASH 2021 – ENG


ZUMA-5, ELARA
ASH 2021
Part I: CAR-T cells on the way


ASH 2021
Part II: Bi-specific antibodies as an attractive agent
Follicular Lymphoma – ENG


ASH 2021
Novel immunotherapy approaches to R/R follicular…


FOLL12
ASH 2021
MRD monitoring in follicular lymphoma is extremely…


ASH 2021
Active new therapy for 3L+ R/R FL


FOLL12
ASH 2021
First-line options and RM
Follicular Lymphoma – GER/ITA


FOLL12
ASH 2021
Ruolo del monitoraggio della malattia minima residua…


ASH 2021
Mosunetuzumab + Lenalidomid beim r/r FL


FOLL12
ASH 2021
Rituximab-Erhaltung nach ICT bleibt Standard
Chronic/Small Lymphocytic Leukemia Discussions: ASH 2021 – ENG


CLL13 / GAIA, FLAIR
ASH 2021
Part II: More data to wait for


BRUIN CLL, SEQUOIA
ASH 2021
Part I: Promising data in CLL
Chronic/Small Lymphocytic Leukemia – ENG


SEQUOIA
ASH 2021
BTKi as new option for untreated CLL/SLL patients


BRUIN
ASH 2021
Pirtobrutinib - promising efficacy in heavily…
Multiple Myeloma Discussions - ENG


iStopMM
ASH 2021
Big data on smoldering multiple myeloma: the iStopMM…


CASSIOPEIA, Griffin, GMMG-HD7, HOVON 143, etc.
ASH 2021
NDMM: On the way to cure?


MajesTEC-1, TRIMM-2, Magnetismm-1, MonumenTAL-1
ASH 2021
The immunotherapy tsunami continues - bispecific…


CARTITUDE-1, CARTITUDE-2
ASH 2021
The immunotherapy tsunami continues - CAR-T cells
Newly Diagnosed Multiple Myeloma – ENG


Griffin; CASSIOPEIA; MANHATTAN
ASH 2021
The future is already here - the use of antibodies in…


Griffin
ASH 2021
PFS separation in the Griffin trial


Muknine
ASH 2021
Positive results for high-risk myeloma from the UK


CASSIOPEIA, Griffin
ASH 2021
Quadruple therapy - the treatment of choice in NDMM


GMMG-HD7
ASH 2021
Quadruple regimens for NDMM


HOVON 143
ASH 2021
Triplet therapie in elderly patients


GMMG-HD6 Trial
ASH 2021
No benefit for elotuzumab in NDMM
Newly Diagnosed Multiple Myeloma – GER/NOR/SWE


Griffin, CASSIOPEIA, MANHATTAN
ASH 2021
The future is already here - the use of antibodies in…


GMMG-HD6 Trial, GMMG-HD7 Trial
ASH 2021
Isatuximab + RVd erfogreich, Elotuzumab nicht


CASSIOPEIA, Griffin
ASH 2021
Quadrupletts Dara-VTd bzw. Dara-RCd erste Optionen bei…


Griffin
ASH 2021
PFS separation in the Griffin trial
Relapsed/Refractory Multiple Myeloma – ENG


BELLINI
ASH 2021
Personalized medicine with venetoclax


MajesTEC-1; Magnetismm-1; CARTITUDE-1
ASH 2021
New bispecific antibodies and CAR-T cells for RRMM…


MonumenTAL-1, TRIMM-2
ASH 2021
talquetamab & cevostamab: bispecific antibodies beyond…


ASH 2021
TAK-573 - a really new mechanism of treatment in…


CARTITUDE-1
ASH 2021
cilta-cel: early, deep and durable responses in heavily…


MonumenTAL-1
ASH 2021
Not another BCMA drug


CARTITUDE-1
ASH 2021
Is CAR-T cell treatment better in heavly pretreated…


MajesTEC-1
ASH 2021
Update on bispecific antibody teclistamab


CONPET
ASH 2021
KRd consolidation reverses PET positivity in 1/3 of the…


CARTITUDE-1
ASH 2021
cilta-cel highly effective in heavily pretreated…


Magnetismm-1
ASH 2021
Elranatamab - a new bispecific antibody in RRMM
Relapsed/Refractory Multiple Myeloma – GER/NOR/SWE


CARTITUDE-1
ASH 2021
cilta-cel hoch erfolgreich bei stark vorbehandelten…


MajesTEC-1, Magnetismm-1, CARTITUDE-1
ASH 2021
New bispecific antibodies and CAR-T cells for RRMM…


MonumenTAL-1, TRIMM-2
ASH 2021
Talquetamab und Cevostamab: Neue bispezifische Ak…


CARTITUDE-1
ASH 2021
cilta-cel: frühes, tiefes, lang anhaltendes Ansprechen…


MajesTEC-1
ASH 2021
Bispezifischer Antikörper Teclistamab beim r/r MM


MonumenTAL-1, Magnetismm-3
ASH 2021
CAR-T oder bispezifische MoAk in der Rezidivtherapie -…


ASH 2021
TAK-573 - a really new mechanism of treatment in…


CONPET
ASH 2021
KRd consolidation reverses PET-positivity in 1/3 of the…
Smoldering Myeloma / MGUS – ENG


iStopMM
ASH 2021
Myeloma precursor disease 2021


iStopMM
ASH 2021
MGUS and COVID-19 risk


iStopMM
ASH 2021
New reference values for light chains in multiple…
Smoldering Myeloma / MGUS – NOR/SWE/GER


iStopMM
ASH 2021
New reference values for light chains in multiple…


iStopMM
ASH 2021
Myeloma precurser disease 2021


iStopMM, PROMISE
ASH 2021
Prävalenz und Risikostratifikation beim SMM